GO:0090027 negative regulation of monocyte chemotaxis: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090027 describes any process that decreases the frequency, rate, or extent of monocyte chemotaxis, a critical braking mechanism in inflammation.
• Endogenous inhibitors such as HMGB1 at high concentrations, BMP antagonists Drm/Gremlin and Dan, CAP37, and a retroviral P15E-related factor can suppress monocyte migration.
• Dysregulation of monocyte chemotaxis contributes to chronic inflammatory diseases, autoimmune conditions, and tumor immune microenvironment remodeling.
• Macrophage polarization states (M1 vs. M2) are linked to distinct gene signatures that influence monocyte recruitment and subsequent function.
• Long non-coding RNAs are emerging as regulators of monocyte chemotaxis in autoimmune cutaneous disease.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of candidate genes in negative regulation of monocyte chemotaxis.
Description
Monocyte chemotaxis is the directed migration of monocytes along chemical gradients toward sites of inflammation or injury. While much attention has focused on positive regulators that recruit monocytes, the negative regulation of this process (GO:0090027) provides essential brakes that prevent excessive or prolonged monocyte infiltration. This GO term is defined as any process that decreases the frequency, rate, or extent of monocyte chemotaxis. Understanding these inhibitory mechanisms is critical because unchecked monocyte recruitment drives chronic inflammatory diseases, autoimmune disorders, and tumor progression. Several endogenous factors have been identified as negative regulators of monocyte chemotaxis. For example, high concentrations of HMGB1 can inhibit monocyte migration, acting as a negative feedback signal. Bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits to suppress monocyte chemotaxis. CAP37, a neutrophil-derived mediator, also modulates monocyte recruitment. Additionally, a retroviral P15E-related chemotaxis inhibitor produced by IL-1-treated endothelial cells may serve as a negative feedback mechanism in vascular responses to monokines. These findings highlight the diversity of molecules that fine-tune monocyte trafficking. In the era of CRISPR gene editing, researchers can now dissect the genetic basis of negative regulation of monocyte chemotaxis by generating knockout, point-mutation, knock-in, and overexpression models. Such studies are essential for identifying therapeutic targets in inflammatory and autoimmune diseases, where restoring negative regulation could mitigate pathology.
negative regulation of monocyte chemotaxis At A Glance
| GO ID | GO:0090027 |
|---|---|
| GO term | negative regulation of monocyte chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the frequency, rate, or extent of monocyte chemotaxis |
| Regulatory direction | Negative |
| Target process | Monocyte chemotaxis (GO:0002548) |
| Associated cell type | Monocyte |
| Example regulators | HMGB1, Drm/Gremlin, Dan, CAP37, P15E-related inhibitor |
What Is GO:0090027?
GO:0090027, negative regulation of monocyte chemotaxis, is a biological process that encompasses any molecular event or pathway that reduces the frequency, rate, or extent of monocyte chemotaxis. In other words, it includes mechanisms that dampen or stop the directed migration of monocytes toward chemoattractants. This regulation can occur through soluble inhibitors, receptor antagonists, intracellular signaling brakes, or changes in gene expression that alter the migratory capacity of monocytes.
Why Is negative regulation of monocyte chemotaxis Important in Cell Biology?
Negative regulation of monocyte chemotaxis is essential for resolving inflammation and preventing tissue damage. Without adequate braking mechanisms, excessive monocyte recruitment can lead to chronic inflammatory diseases, autoimmune pathology, and a tumor-promoting immune microenvironment. Understanding these inhibitory pathways offers opportunities for therapeutic intervention, particularly in conditions where monocyte infiltration is detrimental.
• Prevents excessive monocyte infiltration and tissue damage during inflammation.
• Dysregulation is linked to autoimmune cutaneous diseases and chronic inflammation.
• Influences tumor immune microenvironment and response to immunotherapy.
• Contributes to muscle tissue inflammation in idiopathic inflammatory myopathy.
• Macrophage polarization states (M1/M2) are associated with distinct gene signatures that affect monocyte recruitment.
• Provides targets for anti-inflammatory drug development.
• Helps explain negative feedback loops in vascular responses to monokines.
• Relevant to understanding resolution of inflammation and tissue repair.
• CRISPR screening can identify novel negative regulators of monocyte chemotaxis.
• Potential to modulate monocyte trafficking in cancer and autoimmune diseases.
What Happens During negative regulation of monocyte chemotaxis?
Inhibition by soluble factors
In simple terms: Certain molecules in the environment can tell monocytes to stop moving.
Soluble factors such as high concentrations of HMGB1 can inhibit monocyte migration, acting as a negative feedback signal. Similarly, a retroviral P15E-related chemotaxis inhibitor produced by IL-1-treated endothelial cells suppresses monocyte chemotaxis, suggesting a negative feedback loop in vascular responses. CAP37, a neutrophil-derived mediator, also modulates monocyte recruitment.
Interference with chemoattractant gradients
In simple terms: Some proteins block the signals that attract monocytes.
Bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis, likely by interfering with chemoattractant gradients or receptor signaling.
Intracellular signaling brakes
In simple terms: Inside the monocyte, certain pathways can put the brakes on migration.
Intracellular signaling molecules may dampen the response to chemoattractants. For example, macrophage polarization states are associated with distinct gene signatures that can influence monocyte recruitment and subsequent function. However, specific intracellular brakes in monocytes are less characterized and require further study.
Regulation by non-coding RNAs
In simple terms: Long non-coding RNAs can control genes that affect monocyte movement.
Long non-coding RNAs have been implicated in autoimmune cutaneous disease and may regulate monocyte chemotaxis through modulation of gene expression. This represents an emerging layer of negative regulation.
Tumor microenvironment modulation
In simple terms: Tumors can change how monocytes move to escape immune attack.
Androgen receptor blockade resistance in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment, which may include changes in monocyte recruitment and function. This highlights how pathological conditions can dysregulate negative regulation of monocyte chemotaxis.
Key Genes Involved in GO:0090027 negative regulation of monocyte chemotaxis
The following genes and proteins have been implicated in the negative regulation of monocyte chemotaxis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HMGB1 | At high concentrations, inhibits monocyte migration | Negative feedback regulator; target for anti-inflammatory strategies |
| GREM1 (Drm) | BMP antagonist, interacts with Slits to inhibit monocyte chemotaxis | Potential therapeutic target in inflammation |
| DAN (NBL1) | BMP antagonist, negative regulator of monocyte chemotaxis | Modulates chemotaxis in developmental and inflammatory contexts |
| AZU1 (CAP37) | Neutrophil-derived mediator, modulates monocyte recruitment | Links neutrophil activity to monocyte trafficking |
| P15E-related factor | Retroviral-related chemotaxis inhibitor produced by endothelial cells | Negative feedback in vascular responses |
| AR | Androgen receptor; its blockade alters tumor immune microenvironment | Implications for prostate cancer immunotherapy |
| LncRNAs | Long non-coding RNAs regulate gene expression in autoimmune cutaneous disease | Emerging regulators of monocyte chemotaxis |
| M1/M2 markers | Gene signatures associated with macrophage polarization | Influence monocyte recruitment and function |
| IL-1 | Induces endothelial cells to produce chemotaxis inhibitor | Cytokine link to negative regulation |
| SLIT2 | Interacts with BMP antagonists to regulate chemotaxis | Axon guidance molecule with immune functions |
| ROBO | Receptor for Slits, may mediate negative regulation | Potential signaling node |
| CXCL12 | Chemokine that can be modulated by negative regulators | Context-dependent effects |
| CCL2 | Major monocyte chemoattractant, target of negative regulation | Key positive regulator, indirectly affected |
| TGF-beta | Can influence monocyte migration and polarization | Immunosuppressive cytokine |
| IL-10 | Anti-inflammatory cytokine, may inhibit monocyte chemotaxis | Negative regulator of inflammation |
| TNF-alpha | Pro-inflammatory cytokine, can indirectly affect chemotaxis | Context-dependent |
| IFN-gamma | M1 polarization marker, modulates monocyte recruitment | Th1 immune response |
| LPS | Induces M1 polarization, alters chemotaxis | Inflammatory stimulus |
How Is negative regulation of monocyte chemotaxis Regulated?
The negative regulation of monocyte chemotaxis is itself subject to regulation. For example, IL-1 treatment of endothelial cells induces the production of a retroviral P15E-related chemotaxis inhibitor, suggesting a cytokine-driven negative feedback loop. Macrophage polarization states, influenced by cytokines such as IFN-gamma and IL-10, are associated with distinct gene signatures that can affect monocyte recruitment. Additionally, long non-coding RNAs may regulate the expression of genes involved in monocyte chemotaxis in autoimmune diseases. These layers of regulation ensure that monocyte trafficking is tightly controlled.
negative regulation of monocyte chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGB1 | Chronic inflammation | Knockout mice, monocyte-specific overexpression |
| GREM1 | Inflammatory diseases | Knock-in of point mutations, KO |
| AR | Prostate cancer | Knockout in prostate cancer cell lines, xenografts |
| LncRNAs | Autoimmune cutaneous disease | Knockdown/overexpression in keratinocytes or monocytes |
| CAP37 | Neutrophil-mediated inflammation | Knockout in neutrophil-like cells |
Autoimmune cutaneous disease
Long non-coding RNAs have been implicated in autoimmune cutaneous diseases, where they may regulate monocyte chemotaxis and contribute to pathogenesis. Dysregulated negative regulation could lead to excessive monocyte infiltration and tissue damage.
Prostate cancer and immunotherapy resistance
Androgen receptor blockade resistance in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment, potentially involving changes in monocyte recruitment and negative regulation of chemotaxis. This may contribute to resistance to enzalutamide.
Idiopathic inflammatory myopathy
Muscle tissue cell diversity and clinical implications in idiopathic inflammatory myopathy involve immune cell infiltration, including monocytes. Negative regulation of monocyte chemotaxis may be impaired in these conditions.
Chronic inflammation
Defects in negative regulation of monocyte chemotaxis can lead to chronic inflammatory states, as seen in various diseases where monocyte infiltration is a hallmark.
From negative regulation of monocyte chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate monocyte chemotaxis? | CRISPR knockout in monocyte cell line (e.g., THP-1) |
| Does a specific point mutation in gene Y alter its inhibitory function? | CRISPR point mutation knock-in |
| Can overexpression of gene Z enhance negative regulation? | CRISPR overexpression (e.g., CRISPRa) in monocytes |
| What is the role of a non-coding RNA in monocyte chemotaxis? | CRISPR knockout or knockdown of lncRNA |
| Can we identify novel negative regulators? | Genome-wide CRISPR library screening in monocyte chemotaxis assay |
| Does tagging gene A affect its localization and function? | CRISPR tagged knock-in (e.g., GFP) in monocytes |
How to Study the negative regulation of monocyte chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on chemotaxis | Identify negative regulators |
| RNA-seq | Gene expression changes | Discover signatures linked to regulation |
| Boyden chamber assay | Monocyte migration | Quantify chemotaxis inhibition |
| Microfluidic chemotaxis | Real-time migration dynamics | Study gradient sensing |
| Proteomics | Protein secretion profiles | Find soluble inhibitors |
| Flow cytometry | Monocyte surface markers | Assess polarization states |
| CRISPRa overexpression | Gain-of-function effects | Test if gene enhances inhibition |
| Live-cell imaging | Cell movement | Visualize chemotaxis in real time |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses monocyte chemotaxis, revealing novel negative regulators.
Transcriptomics and RNA-seq
RNA sequencing of monocytes under different conditions can reveal gene expression signatures associated with negative regulation of chemotaxis, as seen in macrophage polarization studies.
Chemotaxis assays
In vitro chemotaxis assays using Boyden chambers or microfluidic devices measure monocyte migration in response to chemoattractants, allowing quantification of negative regulation.
Proteomics and secretomics
Proteomic analysis of conditioned media can identify soluble factors that inhibit monocyte chemotaxis, such as P15E-related inhibitor.
How CRISPR Can Be Used to Study GO:0090027 negative regulation of monocyte chemotaxis
Knockout
CRISPR knockout of candidate genes in monocyte cell lines (e.g., THP-1) can determine whether the gene is required for negative regulation of monocyte chemotaxis. Loss of a negative regulator would be expected to increase chemotaxis.
Point Mutation
Introducing specific point mutations via CRISPR can dissect the functional domains of negative regulators, such as HMGB1 or Drm/Gremlin, to see how they inhibit chemotaxis.
Knock-in
Knock-in of tagged versions (e.g., GFP) of genes like GREM1 allows visualization of protein localization and interaction with Slits during chemotaxis.
Overexpression
CRISPR activation (CRISPRa) can overexpress candidate negative regulators to test whether increased levels further suppress monocyte chemotaxis, potentially identifying therapeutic targets.
How EDITGENE Supports negative regulation of monocyte chemotaxis Research
Researchers studying negative regulation of monocyte chemotaxis-related genes often need to determine whether a candidate gene is causally involved in suppressing monocyte migration. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of monocyte chemotaxis research.
Frequently Asked Questions About negative regulation of monocyte chemotaxis
What is negative regulation of monocyte chemotaxis?
It is any process that decreases the frequency, rate, or extent of monocyte chemotaxis, as defined by GO:0090027.
What genes are involved in negative regulation of monocyte chemotaxis?
Genes such as HMGB1, GREM1 (Drm), DAN, AZU1 (CAP37), and AR have been implicated, along with long non-coding RNAs.
How is monocyte chemotaxis negatively regulated?
Through soluble inhibitors like HMGB1 and P15E-related factor, BMP antagonists, and intracellular signaling brakes.
What diseases are associated with defective negative regulation of monocyte chemotaxis?
Autoimmune cutaneous diseases, prostate cancer, idiopathic inflammatory myopathy, and chronic inflammation.
What is the GO ID for negative regulation of monocyte chemotaxis?
GO:0090027.
How can CRISPR be used to study negative regulation of monocyte chemotaxis?
CRISPR knockout, knock-in, point mutation, and overexpression can test the causal role of candidate genes in monocyte migration.
What are the synonyms for GO:0090027?
There are no synonyms listed for this term.
What cell types are involved in negative regulation of monocyte chemotaxis?
Monocytes are the target cells, but endothelial cells, neutrophils, and other immune cells can produce regulatory factors.
What is the role of HMGB1 in monocyte chemotaxis?
At high concentrations, HMGB1 can inhibit monocyte migration, acting as a negative regulator.
How does Drm/Gremlin inhibit monocyte chemotaxis?
Drm/Gremlin interacts with Slits and acts as a negative regulator of monocyte chemotaxis.
Conclusion
Negative regulation of monocyte chemotaxis (GO:0090027) is a vital biological process that prevents excessive monocyte infiltration and maintains immune homeostasis. Key regulators such as HMGB1, Drm/Gremlin, Dan, CAP37, and P15E-related factor have been identified, and their dysregulation is linked to autoimmune diseases, cancer, and chronic inflammation. CRISPR-based gene editing offers powerful tools to dissect these pathways and identify new therapeutic targets. EDITGENE provides end-to-end CRISPR services to support research in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 2. Xu P et al.. 2023. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.. J Immunother Cancer 11(5) PMID: 37147019
- 3. Zhu H et al.. 2025. Characterization of Muscle Tissue Cell Diversity and Clinical Implications in Idiopathic Inflammatory Myopathy.. J Cachexia Sarcopenia Muscle 16(5):e70043 PMID: 40874258
- 4. Rouhiainen A et al.. 2004. Regulation of monocyte migration by amphoterin (HMGB1).. Blood 104(4):1174-82 PMID: 15130941
- 5. Chen B et al.. 2004. Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis.. J Immunol 173(10):5914-7 PMID: 15528323
- 6. Pereira HA. 1995. CAP37, a neutrophil-derived multifunctional inflammatory mediator.. J Leukoc Biol 57(6):805-12 PMID: 7790760
- 7. Wang JM et al.. 1989. Production of a retroviral P15E-related chemotaxis inhibitor by IL-1-treated endothelial cells. A possible negative feedback in the regulation of the vascular response to monokines.. J Immunol 142(6):2012-7 PMID: 2537869
- 8. Muntyanu A et al.. 2022. Novel role of long non-coding RNAs in autoimmune cutaneous disease.. J Cell Commun Signal 16(4):487-504 PMID: 34346026
